Lung cancer is one of the most challenging cancers to diagnose and treat, making precision in immunohistochemistry (IHC) analysis critical. At OptraSCAN, our PD-L1 lung cancer algorithm enhances the assessment, supporting researchers in delivering objective and reliable interpretations for PD-L1 IHC in both tumor and immune cells. Designed for research use, this advanced solution brings automation and consistency to analysis, advancing lung cancer research with digital pathology solutions and artificial intelligence for cancer diagnostics*.
The OptraSCAN's PD-L1 Lung Cancer Algorithm is an automated image analysis tool that evaluates PD-L1 expression by detecting both partial and complete membrane staining on tumor cells, as well as membrane and cytoplasmic staining on immune cells, within a single scan. Leveraging imaging with digital slide scanners, this advanced approach allows researchers to evaluate PD-L1 expression with improved objectivity and reliability, ensuring consistency across samples in digital histopathology.
With minimal human intervention, the PD-L1 algorithm evaluates PD-L1-positive cells on both tumor and immune cells, generating reproducible results to support objective analysis using digital pathology.
The algorithm calculates PD-L1-positive cells (tumor, lymphocytes, and macrophages) relative to total tumor cells, delivering a comprehensive view of PD-L1 expression across tumor and immune cells using artificial intelligence.
Integrated with Integrated with brightfield slide scanners and fluorescence scanners, the algorithm assesses tumor area adequacy by confirming at least 100 viable tumor cells, leveraging a computer-aided region detection system powered by an artificial neural network.
A case management and reporting module streamlines documentation and results handling, allowing efficient data management for pathology workflows with secure cloud storage for pathology data.
High-resolution whole slide images are captured using OptraSCAN’s advanced scanning technology, maintaining cellular detail with best digital pathology scanners for research.
The algorithm confirms the presence of 100 viable tumor cells, ensuring adequacy for PD-L1 interpretation using tissue analysis with artificial intelligence.
The PD-L1 algorithm assesses PD-L1 expression patterns, including both membrane and cytoplasmic staining, and categorizes PD-L1-positive cells in digital pathology workflows.
The system generates detailed scores and reports, enabling researchers to analyze and document findings with ease. It is also useful as education tools and e-learning platforms for pathology students.
Automated analysis minimizes subjective variation, supporting more consistent PD-L1 assessments with digital pathology slide scanners.
The automated evaluation process allows researchers to focus on critical tasks, optimizing workflow and reducing turnaround time with high-speed whole slide scanners for large labs.
Early and accurate assessment of PD-L1 expression aids in effective research decisions, facilitating advancements in lung cancer research with affordable whole slide imaging for labs.
The effectiveness of our Cervical Cancer Analysis Algorithm is supported by rigorous research and clinical validation in 9 hospitals across 10,000 patients as certified by DBT. Utilizing cloud-based digital pathology workflows, we collaborate with leading institutions and experts in the field to ensure our solutions meet the highest standards of accuracy and reliability. Our virtual pathology platforms for telemedicine makes commitment to continuous improvement by refining our algorithms based on the latest scientific findings and clinical feedback to facilitate remote diagnostics* and support rural labs with remote pathology systems, resulting in our algorithm being recognized and awarded by the Government of India.
OptraSCAN’s PD-L1 Lung Cancer Algorithm is built on rigorous research and validated to ensure the highest standards of accuracy and reliability. Our work, published in the prestigious Nature journal, underscores the technology's significance in advancing lung cancer diagnostics*. Through continuous refinement and partnerships with top institutions and clinical experts, our algorithm stays aligned with the latest scientific breakthroughs, providing pathologists with cutting-edge tools for precision and reliability in PD-L1 analysis for histology and cytology.
OptraSCAN’s PD-L1 Lung Cancer Algorithm empowers lung cancer researchers with a reliable and efficient solution for PD-L1 expression analysis. By leveraging automation, pathology scanners with advanced imaging features, and fluorescence slide imaging for detailed analysis, we enable objective and consistent results, contributing to meaningful progress in lung cancer research.
For more information about our PD-L1 Lung Cancer Algorithm or to schedule a demonstration, please contact us at info@optrascan.com. Let’s advance cancer research together through innovation!
